Actively Recruiting
The Baltimore Polycystic Kidney Disease Clinical and Translational Core Study
Led by University of Maryland, Baltimore · Updated on 2025-09-11
350
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of Maryland, Baltimore
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating autosomal dominant polycystic kidney disease (ADPKD) by establishing a Mid-Atlantic cohort of 350 adults with this condition. The study aims to support high-quality clinical and translational research by collecting detailed clinical information and biological samples. It focuses on understanding the progression of ADPKD and developing a collaborative network to facilitate future studies and trials. This observational study involves thorough baseline clinical assessments including kidney function, total kidney volume, family and clinical history, cardiac function, vascular stiffness, and quality of life. Biological samples such as serum, plasma, urine, and DNA will be collected to create a biobank. No treatments or interventions are given, and an electronic registry will be maintained to support future research participation. Participants will undergo baseline and follow-up assessments over at least three years, including MRI scans to measure kidney volume and annual quality of life evaluations. The study will track the development of ADPKD complications and changes in symptoms. This ongoing observation will help researchers understand the disease better, with no direct treatment involved. The total duration for participation will extend up to three years with regular evaluations.
CONDITIONS
Brief Title
PKD Clinical and Translational Core Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 and older
- Confirmed ADPKD by genetic testing or ultrasound criteria with family history or specified cyst counts
- Ability to provide written informed consent and comply with study requirements
- Glomerular Filtration Rate (GFR) greater than 15 ml/min/1.73m2
You will not qualify if you...
- End Stage Renal Disease, currently on dialysis, or prior kidney transplant
- Pregnant, lactating, or planning pregnancy in the next 6 weeks
- Presence of another systemic disease such as cancer or lupus
- Life expectancy less than 2 years
- Current participation in a drug treatment trial
- Non English speaking
- Uncontrolled diabetes with A1C 7.0 or higher within 6 months or on multiple oral hypoglycemic agents
- Diabetic nephropathy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 3 years
Participants are observed over time to monitor the progression of autosomal dominant polycystic kidney disease (ADPKD) and associated health changes without receiving any treatment interventions.
Baseline visit and annual follow-up visits for up to 3 years
Trial Site Locations
Total: 1 location
1
University of Maryland School of Medicine General Clinical Research Center
Baltimore, Maryland, United States, 21201
Actively Recruiting
Research Team
C
Charalett E Diggs, RN, MSN
K
Karkleen Schuhart
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here